Your browser doesn't support javascript.
loading
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.
Altman, Matthew C; Segnitz, R Max; Larson, David; Jayavelu, Naresh Doni; Smith, Malisa T; Patel, Sana; Scadding, Guy W; Qin, Tielin; Sanda, Srinath; Steveling, Esther; Eifan, Aarif O; Penagos, Martin; Jacobson, Mikila R; Parkin, Rebecca V; Shamji, Mohamed H; Togias, Alkis; Durham, Stephen R.
Afiliación
  • Altman MC; Systems Immunology Division, Benaroya Research Institute, Seattle; Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle. Electronic address: maltman@benaroyaresearch.org.
  • Segnitz RM; Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle.
  • Larson D; Immune Tolerance Network, Bethesda.
  • Jayavelu ND; Systems Immunology Division, Benaroya Research Institute, Seattle.
  • Smith MT; Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle.
  • Patel S; Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle.
  • Scadding GW; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Qin T; Immune Tolerance Network, Bethesda.
  • Sanda S; Madison Clinic for Pediatric Diabetes, University of California San Francisco, San Francisco.
  • Steveling E; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Eifan AO; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Penagos M; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Jacobson MR; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Parkin RV; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Shamji MH; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
  • Togias A; The National Institute of Allergy and Infectious Disease, Bethesda.
  • Durham SR; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, London.
J Allergy Clin Immunol ; 152(5): 1247-1260, 2023 11.
Article en En | MEDLINE | ID: mdl-37460024
BACKGROUND: Allergen immunotherapy (AIT) is a well-established disease-modifying therapy for allergic rhinitis, yet the fundamental mechanisms underlying its clinical effect remain inadequately understood. Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy was a randomized, double-blind, placebo-controlled trial of individuals allergic to timothy grass who received 2 years of placebo (n = 30), subcutaneous immunotherapy (SCIT) (n = 27), or sublingual immunotherapy (SLIT) (n = 27) and were then followed for 1 additional year. OBJECTIVE: We used yearly biospecimens from the Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy study to identify molecular mechanisms of response. METHODS: We used longitudinal transcriptomic profiling of nasal brush and PBMC samples after allergen provocation to uncover airway and systemic expression pathways mediating responsiveness to AIT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01335139, EudraCT Number: 2010-023536-16. RESULTS: SCIT and SLIT demonstrated similar changes in gene module expression over time. In nasal samples, alterations included downregulation of pathways of mucus hypersecretion, leukocyte migration/activation, and endoplasmic reticulum stress (log2 fold changes -0.133 to -0.640, false discovery rates [FDRs] <0.05). We observed upregulation of modules related to epithelial development, junction formation, and lipid metabolism (log2 fold changes 0.104 to 0.393, FDRs <0.05). In PBMCs, modules related to cellular stress response and type 2 cytokine signaling were reduced by immunotherapy (log2 fold changes -0.611 to -0.828, FDRs <0.05). Expression of these modules was also significantly associated with both Total Nasal Symptom Score and peak nasal inspiratory flow, indicating important links between treatment, module expression, and allergen response. CONCLUSIONS: Our results identify specific molecular responses of the nasal airway impacting barrier function, leukocyte migration activation, and mucus secretion that are affected by both SCIT and SLIT, offering potential targets to guide novel strategies for AIT.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Sublingual / Rinitis Alérgica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Sublingual / Rinitis Alérgica Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2023 Tipo del documento: Article